Categories
Our News

Macrophage Pharma Appoints Dr Søren Bregenholt as Chief Executive Officer

Strategic and operational leadership expanded for progressing broad pipeline 

03 September 2019, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr Soren Bregenholt as Chief Executive Officer.

Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: “The Board is delighted to have attracted Søren to Macrophage Pharma. Soren’s outstanding track record from executive positions in both biotech and pharma, as well as his extensive expertise and insight in immunology, will be invaluable as we further develop and commercialise our proprietary Esterase Sensitive Motif™ (ESM™) platform and evolve Macrophage Pharma into a leading biotech company.”

Dr Søren Bregenholt, CEO of Macrophage Pharma, said: “I am excited to join Macrophage Pharma as CEO. The Company’s unique and proprietary ESM™ technology platform is a compelling strategy for inducing transcriptional reprofiling of monocytes and macrophages and represents a differentiated approach to modulation of a centrally important regulator of the immune response across a variety of human diseases. I look forward to working with management and Board to unlock the full therapeutic and commercial potential of the technology in both cancer and non-cancer fields.”

Søren Bregenholt PhD is a Danish national with an extensive operational and strategic track record from the biotech and pharmaceutical industries. He previously held senior executive roles including COO and CBO at Danish biotech companies Symphogen and IO Biotech, respectively. As part of the global R&D Management at Novo Nordisk, Søren was responsible for the global R&D Strategy and External Innovation efforts. Currently, Søren serves as Chairman of the Board at the Danish-Swedish life science organization Medicon Valley Alliance. His academic career, at the University of Copenhagen and Institute Pasteur, Paris, has focussed on immunoregulation and immunopathology in cancer and other diseases.

About Macrophage Pharma

Based on its proprietary Esterase Motif Technology™ (ESM™) platform, Macrophage Pharma is developing a novel and unique class of small molecule therapeutics which modulate immune responses though transcriptional reprogramming of monocytes and macrophages to combat disease. The Company’s novel ESM™ technology platform is designed to deliver small molecule drugs to macrophages in a highly selective manner. The company is developing multiple programs inhibiting key pathways in macrophages in disease including the lead, a macrophage targeted p38MAPi programme for cancer.

The Company was founded by the CRT Pioneer Fund (CPF) and concluded a Series A financing in 2017 with CPF, Aglaia Oncology Fund II, Novo Holdings A/S and M Ventures. Please visit the company website for further information: www.macrophagepharma.com

Contacts:

Macrophage Pharma Limited

Dr Soren Bregenholt, Chief Executive Officer,

Email: [email protected]

Tel: +45 2728 4533

Optimum Strategic Communications

Hollie Vile, Mary Clark, Supriya Mathur

Email: [email protected]

Tel: +44 (0) 203 9509144

Categories
Our News

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

10th September 2018, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today the formation of an international Scientific Advisory Board (SAB).

The Scientific Advisory Board will closely work with management team as it seeks to maximise the potential of its proprietary Esterase Sensitive Motif™ (ESM™) platform and evolve Macrophage Pharma into a leading immunotherapy company.

The Scientific Advisory Board includes:

  • Tanja de Gruijl Ph.D., Professor, Translational Tumor Immunology and Head Immunotherapy Lab at Amsterdam University Medical Centers, Vrije Universiteit Cancer Center, Amsterdam
  • Liza Makowski Ph.D., Professor in the Department of Medicine, Division of Hematology and Oncology, University of Tennessee Health Science Center
  • Alberto Mantovani M.D., Professor, Humanitas University, Scientific Director, Istituto Clinico Humanitas IRCCS, Milan and Chair of Inflammation and Therapeutic Innovation, William Harvey Research Institute, Queen Mary University, London
  • Luke O’Neill Ph.D., Professor and Head of Department of Biochemistry, Trinity College Dublin
  • Mike Owen Ph.D., Chairman of the Board of Ossianix Inc and Director of Zealand Pharma, Avacta Group plc, ReNeuron plc and GammaDelta Therapeutics
  • Laszlo Radvanyi Ph.D., President & Scientific Director, Ontario Institute for Cancer Research (OICR), Toronto, Canada.

On welcoming the members to the SAB, Steven Powell, CEO of Macrophage Pharma, said: “We are delighted to have attracted this stellar group of experts to our Advisory Board.  Their collective knowledge and experience in the field of immunology and oncology will be invaluable as we seek to realise the full therapeutic potential of our ESM™ technology in both cancer and non-cancer fields.”

ENDS

For further information please contact:

Optimum Strategic Communications

Hollie Vile, Mary Clark, Supriya Mathur

Email: [email protected]

Tel: +44 (0) 203 714 1789

About Macrophage Pharma

Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat disease based on its proprietary Esterase Motif Technology™ (ESM™) platform. The Company’s novel ESM™ technology platform is designed to deliver small molecule drugs to macrophages in a highly selective manner. The lead p38MAPi programme is focused on a novel macrophage-targeting p38 MAPK inhibitor. Clinical trials are scheduled to start in 2019. The Company’s R&D pipeline includes additional programmes with proprietary compounds targeting a number of targets.

The Company was founded by the CRT Pioneer Fund (CPF) and concluded a Series A financing in 2017 with CPF, Aglaia Oncology Fund II, Novo Holdings A/S and M Ventures. Please visit the company website for further information: www.macrophagepharma.com

 

Categories
Our News

Macrophage Pharma Appoints Dr Michael Moore as Chairman

11 April 2018, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today that it has appointed Dr. Michael Moore as non-executive Chairman with immediate effect.

Commenting on the appointment, Steven Powell, CEO of Macrophage Pharma, said: “Michael’s outstanding track record in building both private and public biotech companies, as well as his expertise and insight into the field of immunology, will be invaluable as we develop and commercialise our proprietary Esterase Sensitive Motif™ (ESM™) platform and evolve into a leading immunology company.”

Dr Michael Moore, Chairman of Macrophage Pharma, said: “I am impressed by Macrophage Pharma’s unique and proprietary ESM™ technology platform and its differentiated approach to the modulation of immune function in disease. I look forward to working with the Executive team and my new Board colleagues as we seek to realise the full therapeutic potential of ESM™ technology in both cancer and non-cancer fields.”

Dr Michael Moore has extensive experience in drug discovery and development and is currently a non-executive director of several private and public bioscience companies, including Mission Therapeutics, of which he was Founder Chairman, NASDAQ-listed Trillium Therapeutics Inc. and Mironid Limited.  He is currently Chairman of Chronos Therapeutics and was Founder Chairman of PsiOxus Therapeutics.  Dr Moore was previously CEO of Piramed, acquired by Roche in 2008, and Research Director and CSO of Xenova Group plc. Prior to joining the UK biotechnology sector, he had an extensive academic research career, principally at the Paterson Institute for Cancer Research and the University of Manchester Medical School, where he was Honorary Reader in immunology and oncology.  Dr Moore holds PhD and DSc degrees from the University of Nottingham, fellowship of the Royal College of Pathologists and is a past Chairman of Cancer Research UK’s drug discovery committee.

ENDS       

For further information please contact:

Optimum Strategic Communications

Hollie Vile, Mary Clark, Supriya Mathur

Email: [email protected]

Tel: +44 (0) 203 714 1789

About Macrophage Pharma

Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat disease based on its proprietary Esterase Motif Technology™ (ESM™) platform. The Company’s novel ESM™ technology platform is designed to deliver small molecule drugs to macrophages in a highly selective manner. The lead p38MAPi programme is focused on a novel macrophage-targeting p38 MAPK inhibitor. Clinical trials are scheduled to start in 2019. The Company’s R&D pipeline includes additional programmes with proprietary compounds targeting a number of targets.

The Company was founded by the CRT Pioneer Fund (CPF) and concluded a Series A financing in 2017 with CPF, Aglaia Oncology Fund II, Novo Holdings A/S and M Ventures. Please visit the company website for further information: www.macrophagepharma.com

Categories
Our News

Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference

7 November 2017, Windsor, UK: Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that two abstracts will be presented on its proprietary Esterase Sensitive Motif™ (ESM™) technology and its lead development candidate, MPL-5821, a macrophage targeted p38 MAP kinase inhibitor, at the 32nd Annual Society for Immunotherapy of Cancer (SITC) conference, held on 10-11 November  2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

  • The first poster (P479) entitled “MPL-5821, an ESM™-p38 MAPK Inhibitor, modulates macrophage plasticity leading to enhanced IL-12p70 and IFN, reduced IL-10 and the reversal of macrophage induced T-Cell suppression”[i] describes the preliminary in vitro characterisation of MPL-5821, contrasting it with conventional inhibitors, with reference to its cell type specificity, sparing of myelomonocytic – lymphocyte communication and ability to reverse macrophage driven lymphocyte immunosuppression.

The data presented demonstrates that MPL-5821 modulates the macrophage phenotype to IL-12p70Hi / IL-10Lo and reverses the M2 macrophage suppression of T-cell functionality. The ESM™ cell selectivity differentiates MPL-5821 from non-targeted p38 MAPK inhibitors by its sparing of other immune cells such as lymphocytes. MPL-5821 enables the maintenance of the myelomonocytic/lymphocyte IL-12p70/IFNg axis, key to an effective anti-tumour immune response.

  • The second poster (P333), “MPL-5821, an ESM™-p38 MAPK Inhibitor, Enhances Tumor Immune Response and M1 Macrophage Polarization In A 3D Ex Vivo System Utilizing Fresh Tumor Microspheroids Of Lung Cancer Patients,”[ii] evaluates the immunomodulatory effect of MPL-5821 in a 3D ex vivo assay of lung cancer.

The data presented demonstrates that the lung patient derived ex-vivo approach indicates that MPL-5821 may alleviate myelomonocytic cell induced immunosuppression and enhance antigen responsiveness suggesting potential clinical implications in the treatment of lung cancer.

David Moffat, Director of Chemistry at Macrophage Pharma, said: “We are very pleased to present data on our lead programme MPL-5821 at SITC.  Results demonstrate that targeted inhibition of p38 MAP kinase in macrophages and dendritic cells is an attractive approach to relieve immunosuppression in the tumour microenvironment and provide validation of Macrophage Pharma’s ESM™ technology platform.  We are delighted to be able to share these meaningful findings with the rest of the immunotherapy community, and are actively advancing this programme into clinical studies in 2018.”

A copy of the posters and abstracts can be viewed and downloaded by clicking here

For further information please contact:

Optimum Strategic Communications

Hollie Vile, Mary Clark, Supriya Mathur

Email: [email protected]

Tel: +44 (0) 203 714 1789

 

About Macrophage Pharma Limited 

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses by modulating the tumour microenvironment.

Its proprietary Esterase Motif Technology™ (ESM™) platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body’s natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.

Founded by the CRT Pioneer Fund (CPF), the Company recently concluded a Series A financing round, led by CPF and joined by three specialist investors, Aglaia Biomedical Ventures BV, Novo Holdings A/S and Merck Ventures. For more information, please visit the company website: www.macrophagepharma.com

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. Established in 1984, SITC is a 501(c)(3) not-for-profit organization with a growing constituency of academic, government, industry, clinical and basic scientists, and practitioners from around the world.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.

 

[i]Poster 479

 Authors: Martin Perry, David Moffat, Justyna Rzepecka, Lucia Janicova, Anastasia Nika, Darryl Turner, Clare Doris, Stephen Anderton

Affiliation: Macrophage Pharma Limited, Windsor, United Kingdom  and Aquila BioMedical Limited, Edinburgh, United Kingdom

[ii] Poster 333

Authors: Melanie Mediavilla-Varela, Melba Marie Page, Jenny Kreahling, Martin Perry, David Moffat, Scott Antonia, Soner Altiok

Affiliation: Nilogen Oncosystems, Tampa, FL, USA  and Macrophage Pharma Limited, Windsor, United Kingdom

 

Categories
Our News

Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures

Merck Ventures Joins Investment Syndicate and the Board of Macrophage

Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that it has raised additional funding from Merck Ventures to complete the Series A Financing announced in January 2017.  Merck Ventures joins the existing investor syndicate of CRT Pioneer Fund (CPF), Novo Holdings A/S and Aglaia Biomedical Ventures BV with an equal size of investment. Senior Investment Director Hakan Goker from Merck Ventures joins Macrophage Pharma’s Board of Directors.

The financing will enable Macrophage Pharma to complete the first clinical study of its lead development candidate, a macrophage targeted p38MAP kinase inhibitor, as well as advancing two additional discovery candidates into preclinical development. The Company is also planning to utilise the additional capital by adding a fourth macrophage-targeted project into its pipeline.

Commenting on the completion of the financing round Ian Miscampbell, Non-Executive Chairman of Macrophage Pharma, said: “We are pleased to welcome Merck Ventures

to our existing investor syndicate.  Their commitment represents further validation of the Company’s novel approach in the immuno-oncology field and enables us to expand our pipeline.”

Hakan Goker, Senior Investment Director at Merck Ventures, added: “We are excited to join this experienced management team and investor syndicate to help translate this immuno-oncology pipeline into clinical development.  Macrophage Pharma impressed us with the initial data generated. The differentiated, novel approach they are following in the TME offers promise for the immuno-oncology armoury of clinicians to address a broad range of cancers.”

Macrophage Pharma’s ESM™ technology platform is designed to deliver small molecule drugs to macrophages in a highly selective manner, activating the body’s natural immune system to fight cancer.  The ESM™ technology platform has the ability to provide next-generation immunotherapies for a number of different cancers and larger patient populations.

The Company’s lead p38MAPi programme is focused on a novel macrophage-targeting p38 MAPK inhibitor. Clinical trials are scheduled to start in 2018. The Company is also developing additional programmes against novel targets centred on a number of proprietary, candidate compounds.

–    ENDS    –

For further information please contact:

Macrophage Pharma

Hollie Vile

Email: [email protected]

Tel: +44 (0) 7729 362 590

 

About Macrophage Pharma Limited 

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses by modulating the tumour microenvironment.

Its proprietary Esterase Motif Technology™ (ESM™) platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body’s natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.

Founded by the CRT Pioneer Fund (CPF), the Company recently raised £9 million in a Series A financing round, led by CPF and two new specialist investors, Novo Holdings A/S and Aglaia Biomedical Ventures BV.

For more information, please visit the company website: www.macrophagepharma.com

About Merck Ventures

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel it invests globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.  www.m-ventures.com